ReviewNature reviews. Microbiology2019
Protozoan persister-like cells and drug treatment failure.
Review in Nature reviews. Microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 153 citations in OpenAlex.
- Active transcriptome remodeling underlies antimony-induced drug tolerance in persister-like Leishmania parasites.PLoS pathogens · 2026Article
- Identification of new Trypanosoma cruzi-specific protein synthesis inhibitors by using a developed high-throughput in vitro translation assay.International journal for parasitology. Drugs and drug resistance · 2026Article
- SNOR promotes translation restart after dormancy.Nature · 2026Article
- Multi-drug tolerance in Leishmania persister-like cells.Communications biology · 2026Article
- Beyond resistance: Emerging methods to dissect drug responses in Leishmania.PLoS pathogens · 2026Review
- Trypanosoma cruzi cell atlas as a single-cell resource for understanding parasite population heterogeneity and differentiation.Nature communications · 2026Article
- A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 3: from lead towards a drug development candidate.The Journal of antimicrobial chemotherapy · 2026Review
- Leishmania major virulence attenuation in vitro: An old conundrum revisited in the omics era.PLoS neglected tropical diseases · 2026Article
- In Vivo Trypanocidal Activity of the Drug Disulfiram Combined with Benznidazole.ACS infectious diseases · 2026Article
- Nonlinear dynamics of Nosema ceranae and the fragile resilience of honeybee colonies under environmental strain.Scientific reports · 2026Article
- A Novel Eukaryotic Ribosome Factor Enables Translation Restart Following Cellular Dormancy.bioRxiv : the preprint server for biology · 2026Article
- Unravelling complex interactions during Toxoplasma, Plasmodium, and Leishmania co-infections in French Guiana.Scientific reports · 2026Article
- High throughput quantitative tracking ofbioRxiv : the preprint server for biology · 2026Article
- Untargeted metabolomics for triaging of cytochrome b inhibitors during Chagas' disease drug discovery.PLoS neglected tropical diseases · 2026Article
- NN-assisted image analysis for quantifying intracellularFrontiers in cellular and infection microbiology · 2026Article
- Trypanosomatid parasites, translational research in a One Health, One World environment.Frontiers in chemistry · 2026Review
- BFD2 mediates inflammation, apoptosis, and pre-anxiety-like behaviors induced by acute Toxoplasma gondii infection.PLoS neglected tropical diseases · 2025Article
- The importance of persistence and dormancy in Trypanosoma cruzi infection and Chagas disease.Current opinion in microbiology · 2025Review
- Putrescine Depletion inPathogens (Basel, Switzerland) · 2025Article
- An Update on Vaccines AgainstPathogens (Basel, Switzerland) · 2025Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Antimicrobial treatment failure threatens our ability to control infections. In addition to antimicrobial resistance, treatment failures are increasingly understood to derive from cells that survive drug treatment without selection of genetically heritable mutations. Parasitic protozoa, such as Plasmodium species that cause malaria, Toxoplasma gondii and kinetoplastid protozoa, including Trypanosoma cruzi and Leishmania spp., cause millions of deaths globally. These organisms can evolve drug resistance and they also exhibit phenotypic diversity, including the formation of quiescent or dormant forms that contribute to the establishment of long-term infections that are refractory to drug treatment, which we refer to as 'persister-like cells'. In this Review, we discuss protozoan persister-like cells that have been linked to persistent infections and discuss their impact on therapeutic outcomes following drug treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.